Therefore, these data suggest that restoring sAPPα levels or enhancing its association with β-secretase 1 in AD patients to rebalance the impaired APP processing could be potential strategies to ameliorate AD symptoms, as also indicated by sAPPα inhibitory effects on Tau phosphorylation [171]. This evidence concerns the gene MAPT and Alzheimer disease.